OGN Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

6.230

Open

6.000

VWAP

6.09

Vol

3.94M

Mkt Cap

1.59B

Low

5.940

Amount

24.03M

EV/EBITDA(TTM)

5.62

Total Shares

260.32M

EV

9.65B

EV/OCF(TTM)

13.79

P/S(TTM)

0.26

Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.

Show More

Events Timeline

(ET)

2026-02-23

07:40:00

Organon Exclusively Licenses Global Rights to Miudella for $27.5M

2026-02-12 (ET)

2026-02-12

12:20:00

Dow Jones Index Falls 1.10% Amid Technology Profit Concerns

2026-02-12

07:50:00

Company Expects FY26 Adjusted EBITDA of $1.9B

2026-02-12

07:40:00

Organon Reports Q4 Revenue of $1.51B

2026-01-28 (ET)

2026-01-28

13:00:00

Organon Successfully Sells JADA System to Laborie Medical Technologies Corp.

2026-01-19 (ET)

2026-01-19

14:20:00

Organon Nexplanon Approved by FDA for Extended Use Up to Five Years

2026-01-08 (ET)

2026-01-08

05:10:00

Organon Enters Agreement with Daiichi Sankyo to Commercialize Nilemdo in Nordic Countries

News

Yahoo Finance

03-24Yahoo Finance

Organon 2025 Financial Results and Outlook Analysis

Fool

Sio Capital Establishes New Position in Organon

NASDAQ.COM

03-20NASDAQ.COM

Sio Capital Initiates New OGN Position

seekingalpha

03-10seekingalpha

Organon Shares Decline Amid Strategic Uncertainty and Weak Earnings

CNBC

War Causes Sharp Decline in Birth Rates in Ukraine and Russia

Newsfilter

02-23Newsfilter

Organon Licenses MIUDELLA® to Enhance Women's Health Commitment

5 Analyst Rating

Wall Street analysts forecast OGN stock price to rise

0 Buy

1 Hold

4 Sell

Strong Sell

Current: 0.000

Low

5.00

Averages

8.50

High

12.00

Current: 0.000

Low

5.00

Averages

8.50

High

12.00

Barclays

Underweight

maintain

$8

AI Analysis

2026-02-24

Reason

Barclays

Price Target

$8

AI Analysis

2026-02-24

maintain

Underweight

Reason

Barclays raised the firm's price target on Organon to $8 from $7.50 and keeps an Underweight rating on the shares. The firm updated the company's model post the Q4 report.

Barclays

Underweight

initiated

$7.50

2025-12-08

Reason

Barclays

Price Target

$7.50

2025-12-08

initiated

Underweight

Reason

Barclays initiated coverage of Organon with an Underweight rating and $7.50 price target. The firm rolled out coverage on the specialty pharmaceuticals industry with a neutral view, saying investor sentiment is improving as companies shift focus to innovation, margin expansion and de-leveraging. The group's pricing headwinds are easing while debt leverage is coming down, the analyst tells investors in a research note. Barclays sees "plenty of opportunity" as the sector "remains in a transition phase."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for OGN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Organon & Co (OGN.N) is 1.88, compared to its 5-year average forward P/E of 4.77. For a more detailed relative valuation and DCF analysis to assess Organon & Co's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

4.77

Current PE

1.88

Overvalued PE

6.25

Undervalued PE

3.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

6.59

Current EV/EBITDA

5.17

Overvalued EV/EBITDA

7.72

Undervalued EV/EBITDA

5.46

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

0.90

Current PS

0.31

Overvalued PS

1.25

Undervalued PS

0.54

Financials

AI Analysis

Annual

Quarterly

Whales Holding OGN

Private Management Group Inc

Trading Trends

People Also Watch

Frequently Asked Questions

What is Organon & Co (OGN) stock price today?

The current price of OGN is 6.11 USD — it has increased 0.33

What is Organon & Co (OGN)'s business?

Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.

What is the price predicton of OGN Stock?

Wall Street analysts forecast OGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OGN is8.50 USD with a low forecast of 5.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Organon & Co (OGN)'s revenue for the last quarter?

Organon & Co revenue for the last quarter amounts to 1.51B USD, decreased -5.34

What is Organon & Co (OGN)'s earnings per share (EPS) for the last quarter?

Organon & Co. EPS for the last quarter amounts to -0.79 USD, decreased -288.10

How many employees does Organon & Co (OGN). have?

Organon & Co (OGN) has 10000 emplpoyees as of March 25 2026.

What is Organon & Co (OGN) market cap?

Today OGN has the market capitalization of 1.59B USD.